YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek. Anthropic's Claude AI recently…
With the third quarter well underway and most second-quarter earnings now in the rearview mirror, investors are starting to look ahead to the rest of 2026 and how best to position their portfolios. Summer Sale - Claim 70% Off TipRanks Unlo…
Syndax Pharmaceuticals (NASDAQ:SNDX) just posted a quarter that nearly doubled revenue, yet shares slipped 2.41% anyway. On its August 4 earnings call, management reported combined sales of $115 million across its two approved drugs, both…
[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell on Wednesday. U.S. stock index futures rose on Wednesday as Wall Street looked to continue…
Harmony Biosciences Holdings, Inc. (HRMY) shares soared 10% in the last trading session to close at $36.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 0.2%…
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the most promising stocks on our list. TheFly reported on June 12 that Guggenheim an…
Quick Read AbbVie (ABBV) proved big pharma will pay up for late-stage immunology with the Apogee deal, reigniting M&A speculation across the biotech sector. Syndax (SNDX) earns the top takeover ranking with two FDA-approved drugs, 224% rev…
(RTTNews) - Syndax Pharmaceuticals (SNDX), a commercial-stage biopharmaceutical company, on Tuesday released data from analysis and Phase 1 trial for Revuforj in treating acute leukemia and acute myeloid leukemia (AML) in patients after he…
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the best small cap stocks to buy for 10x potential. On May 4, Stifel lifted the price target on Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to $46 from $45, reaffirming a Buy rating on th…
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026, the Company granted inducement award…
Earnings Call Insights: Syndax Pharmaceuticals (SNDX) Q1 2026 MANAGEMENT VIEW * “In the first quarter, we delivered over $100 million in combined sales of Revuforj and Niktimvo, underscoring robust demand for both medicines and advancing t…
Syndax Pharmaceuticals logo Key Points Over $100 million in combined Q1 net sales — Revuforj $49M and Niktimvo $55M — with both products annualizing near $200M and Revuforj growth driven by NCCN guideline inclusion and an expanded FDA labe…
Major earnings expected after the bell on Thursday include: * Apple (AAPL [https://seekingalpha.com/symbol/AAPL]) * Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]) * Roku (ROKU [https://seekingalpha.com/symbol/ROKU]) * Twilio (TWLO [ht…
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement a…
Key Points DAFNA Capital Management sold 222,847 SNDX shares in the fourth quarter for an estimated roughly $4 million. Meanwhile, the quarter-end position value decreased by $1.87 million, reflecting both trading and price movements. The…
Key Points Kynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million. Meanwhile, the position's quarter-end value changed by $105.74 million, reflecting both trading…
Kynam Capital Management disclosed in a February 17, 2026, SEC filing that it sold 1,720,949 shares of Cogent Biosciences(NASDAQ:COGT), an estimated $48.38 million trade based on quarterly average pricing. What happened According to a SEC…
Kynam Capital Management trimmed its stake in Viridian Therapeutics(NASDAQ:VRDN), selling 2,957,386 shares in the fourth quarter, an estimated $81.11 million transaction based on quarterly average pricing, according to a February 17, 2026,…
Kynam Capital Management reduced its position in CG Oncology(NASDAQ:CGON), selling 1,059,375 shares in the fourth quarter for an estimated $43.84 million based on quarterly average pricing, according to a February 17, 2026, SEC filing. Wha…
Key Points Kynam Capital reduced its Syndax Pharmaceuticals stake by 469,041 shares in the fourth quarter; the estimated trade size was $8.18 million based on average closing prices for the quarter. Meanwhile, the quarter-end position valu…
Kynam Capital Management disclosed in a February 17, 2026, Securities and Exchange Commission (SEC) filing that it sold 469,041 shares of Syndax Pharmaceuticals(NASDAQ:SNDX), an estimated $8.18 million trade based on quarterly average pric…
Key Points Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in the fourth quarter. The quarter-end position value rose by $10.06 million, reflecting both trading and price movement. The post-trade holding stood at 762,563 shares…
Key Points Sphera Funds bought 279,974 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $7.87 million. The quarter-end position value increased by $12.03 million, reflecting both new shares and stock…
Quick Read uniQure (QURE) upgraded to $35 by RBC and $60 by Wells Fargo, up 53.33% past week, trades at $16.52. Syndax (SNDX) raised to $45, trades at $23.23, Q4 revenue $44.20M up 38%; Erasca (ERAS) gets $24 target, up 305.17% YTD. uniQur…
Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim biotech conference, Chief Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) star…
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as wel…
What happened According to its latest SEC filing dated Feb. 13, 2026, Pale Fire Capital SE initiated a new position in Baxter International(NYSE:BAX), purchasing 2,074,016 shares. The estimated transaction value, calculated using the quart…
Syndax Pharmaceuticals logo Key Points Syndax reported strong commercial momentum entering 2026 with $125 million in annual net sales for Revuforj and $152 million in net sales for Niktimvo in its first 11 months, with both products showin…
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising low-cost stocks to buy now. On February 3, Bank of America analyst Jason Zemansky raised the firm’s price target on Syndax to $28 from $27 and kept a Buy rating. Zemans…
We came across a bullish thesis on Syndax Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on SNDX. Syndax Pharmaceuticals, Inc.'s share was trading at $20.67 as of January 15th.scie…
Syndax Pharmaceuticals, Inc. – Approximately $44 million and $125 million in preliminary (unaudited) Revuforj® (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM…
- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations - - Program will be launched in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Tur…
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will p…
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts – – Retrospective review sho…
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on December 1, 2025, the Company granted inducement…
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will p…